Jun Li, Hannah K. Weir, Melissa A. Jim, and Reda Wilson are with the Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Sallyann M. King is with the Division of Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC. Viraj A. Master is with the Department of Urology and Winship Cancer Institute, School of Medicine, Emory University, Atlanta.
We describe rates and trends in kidney cancer incidence and mortality and identify disparities between American Indian/Alaska Native (AI/AN) and White populations.
To improve identification of AI/AN race, incidence and mortality data were linked with Indian Health Service (IHS) patient records. Analysis focused on residents of IHS Contract Health Service Delivery Area counties; Hispanics were excluded. We calculated age-adjusted kidney cancer incidence (2001-2009) and death rates (1990-2009) by sex, age, and IHS region.
AI/AN persons have a 1.6 times higher kidney cancer incidence and a 1.9 times higher kidney cancer death rate than Whites. Despite a significant decline in kidney cancer death rates for Whites (annual percentage change [APC]?=?-0.3; 95% confidence interval [CI]?=?-0.5, 0.0), death rates for AI/AN persons remained stable (APC = 0.4; 95% CI = -0.7, 1.5). Kidney cancer incidence rates rose more rapidly for AI/AN persons (APC = 3.5; 95% CI = 1.2, 5.8) than for Whites (APC = 2.1; 95% CI = 1.4, 2.8).
AI/AN individuals have greater risk of developing and dying of kidney cancers. Incidence rates have increased faster in AI/AN populations than in Whites. Death rates have decreased slightly in Whites but remained stable in AI/AN populations. Racial disparities in kidney cancer are widening.
Notes
Cites: JAMA. 1984 Jul 27;252(4):487-906737638
Cites: Am J Clin Nutr. 1991 Jun;53(6 Suppl):1535S-1542S2031484
Cites: JAMA. 1999 May 5;281(17):1628-3110235157
Cites: Cancer. 2005 Mar 1;103(5):1045-5315685622
Cites: Cancer Invest. 2005;23(3):240-5515945510
Cites: Am J Prev Med. 2006 Jun;30(6):493-716704943
Cites: J Natl Cancer Inst. 2006 Sep 20;98(18):1331-416985252
Cites: Stat Methods Med Res. 2006 Dec;15(6):547-6917260923
Cites: Cancer. 2007 Nov 15;110(10):2119-5217939129
Cites: Hematol Oncol Clin North Am. 2011 Aug;25(4):651-6521763961
Cites: J Urol. 2012 Jan;187(1):32-822088338
Cites: J Natl Cancer Inst. 2013 Feb 6;105(3):175-20123297039
Cites: Br J Cancer. 2013 Mar 5;108(4):798-81123412105
Cites: Cancer. 2014 May 1;120(9):1290-31424343171
Cites: Am J Public Health. 2014 Jun;104 Suppl 3:S286-9424754557
Cites: World J Urol. 2010 Jun;28(3):247-5220390283
Cites: Med Sci Sports Exerc. 1999 Nov;31(11 Suppl):S547-5210593526
Cites: Stat Med. 2000 Feb 15;19(3):335-5110649300
Cites: Natl Vital Stat Rep. 2001 May 18;49(2):1-3211381674